The increasing use of modern imaging techniques has led to the incidental detection of small renal masses (SRMs), with kidney cancer representing a significant portion of tumors in elderly individuals. To guide treatment decisions for these masses, renal mass biopsy plays a crucial role in distinguishing between benign and malignant lesions. Nephron-sparing surgery (NSS) is typically the gold standard for treating renal cell cancer, especially for lesions less than 7 cm in diameter. However, tumor ablation (TA) has emerged as a viable alternative treatment, offering advantages such as reduced pain, preservation of kidney function, shorter hospital stays, and decreased operative time, particularly beneficial for elderly or comorbid patients with clinical stage T1a masses. While cryoablation and radiofrequency ablation are gaining attention for kidney cancer treatment, the available evidence on their morbidity and oncological outcomes remains limited, leading to uncertainty in their recommendation strength. Comparing tumor ablation to surgery, international guidelines suggest considering tumor ablation as a treatment option for T1 renal masses, but long-term oncological effectiveness remains unclear due to inadequate and poorly matched data. Technical details of CT-guided percutaneous cryoablation are provided, highlighting the importance of precise planning and monitoring to ensure successful treatment. Postoperative care and follow-up involve contrast-enhanced CT scans and blood analyses to assess treatment completeness and potential complications. Oncological outcomes for cT1a tumors after cryoablation have generally been favorable, with local recurrence rates significantly lower than cT1b tumors. Salvage treatments may include re-cryoablation. Alternative energy sources for focal therapy, such as radiofrequency ablation, stereotactic ablative radiotherapy (SABR), microwave ablation, high-intensity focused ultrasound ablation, and non-thermal irreversible electroporation, offer additional options for managing renal masses. While these techniques show promise, further research is needed to establish their long-term efficacy and safety. In conclusion, the management of small renal masses is evolving, with tumor ablation emerging as a valuable option alongside surgery. However, the strength of recommendations for these treatments remains uncertain, necessitating further investigation and data refinement.